Small-cap stocks with growth potential can deliver great share price gains, and Bell Potter thinks they’ve identified two such companies.

They’ve released research reports this week into two companies in the healthcare sector, and are predicting solid gains for both.

Let’s see who they like.

Lumos Diagnostics Ltd (ASX: LDX)

This diagnostic technology company recently reported full-year revenue of US$13.2 million, up 6% on the previous year, and an adjusted EBITDA loss of US$2.8 million, which was a 19% improvement.

The company said it was a “landmark year underpinned by significant regulatory, commercial, and operational achievements that have positioned the Company for future growth”.

The company went on to say:

The year was highlighted by the execution of a transformational six-year U.S. distribution agreement with PHASE Scientific with a value of US$317 million, achievement of U.S. FDA CLIA waiver status for FebriDx, and securing nationwide Medicare reimbursement recognition across all U.S. Medicare Administrative Contractors (MACs). These milestones materially expanded the addressable market opportunity for FebriDx by more than 15 times to over US$1.0 billion per annum and established the foundations for large-scale commercial adoption in the U.S.

The company said FY27 will be about converting the regulatory and commercial milestones achieved in FY26 into sustained revenue growth.

Bell Potter agreed, saying the commercial execution of the FebriDx rollout would be the focus.

The broker is expecting Lumos to hit breakeven in FY29.

Bell Potter has a price target of 25 cents on Lumos, compared to the current price of 10 cents. Lumos Diagnostics is valued at $94.5 million.

Trajan Group Ltd (ASX: TRJ)

This analytical science company delivered second-half EBITDA of $8.1 million, up from $5 million in the first half of the year, but overall full-year earnings were down 14.7%.

Chief Executive Officer Stephen Tomisich said of the result:

FY26 was a year of two halves. While the first quarter created a difficult starting point for the year, the business recovered operationally from Q2 onward, and we delivered a materially stronger second half result. The benefits of Project Neptune and other operational initiatives became increasingly evident in H2, with improved gross margins, stronger nEBITDA and better cost control across the Group. These gains were partly masked in the reported result by the appreciation of the Australian dollar against key trading currencies.

The company’s guidance for the current year is for mid-single-digit organic revenue growth in FY27 and double-digit EBITDA growth.

Bell Potter said the company “is trading at an extremely deep discount, but it will need to turnaround earnings momentum to shift investor sentiment”.

Bell Potter has a price target of 50 cents on Trajan shares compared to 16.5 cents currently.

The post 2 ASX small-cap stocks Bell Potter thinks could return 130% to 200% appeared first on The Motley Fool Australia.

More reading

• Harvey Norman lifts profit and dividend in FY26 earnings result
• WAM Capital trims FY27 dividend after portfolio setback in FY26
• Solstice Minerals extends deep, high-grade copper-gold zones at Nanadie
• Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab
• How much passive income can I earn from $500,000 in superannuation?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Solstice Minerals Ltd (ASX: SLS) share price is in focus after the company reported outstanding deep drilling results at its 100%-owned Nanadie Copper-Gold Project in Western Australia, including a 722.3-metre intercept grading 0.44% copper and 0.13g/t gold.

What did Solstice Minerals report?

• Confirmed a total intercept of 722.3m @ 0.44% Cu, 0.13g/t Au from hole NANRCD005, extending mineralisation over 500m below the current Mineral Resource boundary.
• Significant high-grade sections include 28m @ 1.31% Cu, 0.30g/t Au and 43.3m @ 0.91% Cu, 0.35g/t Au at depth.
• Current Mineral Resource Estimate (MRE) stands at 40.4 million tonnes @ 0.4% Cu, 0.1g/t Au, with the new results indicating strong potential for expansion.
• Assays are pending from a further 14 diamond holes and over 20 Reverse Circulation (RC) holes.
• Solstice holds $45 million in cash and has no debt, providing a solid balance sheet for continued exploration.
• The Nanadie project sits fully within a granted Mining Lease, with step-up drilling programs underway.

What else do investors need to know?

Solstice Minerals’ drilling campaign is expanding the known copper-gold system well beyond previous boundaries, with both scale and grade persisting at depth. The close match between laboratory assays and previously logged visible copper sulphide zones is increasing confidence in Solstice’s geological model and upcoming drill targets.

The company has invested in expanding its exploration camp and core processing facilities, and expects to have multiple rigs operating for the remainder of the year. Drilling results from the nearby Stark Prospect and unexplored extensions north of Nanadie are also expected to flow through in coming months.

What did Solstice Minerals management say?

Nick Castleden, CEO and Managing Director, said:

NANRCD005 is an extraordinary drillhole that marks another defining moment in the rapidly unfolding story at Nanadie. The combined 722.3m @ 0.44% Cu, 0.13g/t Au intercept – inclusive of all post-mineral dykes and low-grade zones – provides definitive evidence that the deposit will continue to deliver scale and grade way beyond the current MRE limits. Within that broad mineralised envelope, we are seeing multiple substantial higher-grade zones such as 28m @ 1.31% Cu, 0.3g/t Au and 43.3m @ 0.91% Cu, 0.35g/t Au – showing that grade as well as scale persist at depth.

What’s next for Solstice Minerals?

Solstice is stepping up both RC and diamond drilling to test for further extensions of the Nanadie deposit, targeting expansion of its current Mineral Resource. With a second RC rig due onsite and a large volume of assay results still pending, investors can expect a steady news flow through the remainder of 2026.

The business is also planning to drill new prospects at Stark and to test previously untested targets along the broader geological corridor. The focus will remain on growing the scale and grade of the copper-gold system and progressing towards updated resources and potential development studies.

Solstice Minerals share price snapshot

Over the past 12 months, Solstice Minerals shares have surged more than 600%, significantly outpacing the All Ordinaries Index (ASX: XAO).

View Original Announcement

The post Solstice Minerals extends deep, high-grade copper-gold zones at Nanadie appeared first on The Motley Fool Australia.

More reading

• Solstice Minerals: Nanadie drilling extends copper-gold system
• Solstice Minerals: Nanadie copper-gold system grows

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Imricor Medical Systems Inc (ASX: IMR) share price is in focus today after the company announced the commercial launch of its Interventional MR (iMR) lab solution in collaboration with global imaging leader Philips. This new combined solution is immediately available in CE-marked markets and is designed to support MR-guided cardiac interventions.

What did Imricor Medical Systems report?

• Commercial launch of a combined iMR lab solution with Philips.
• The solution integrates Philips’ 1.5T BlueSeal MR platform with Imricor’s NorthStar^®, Advantage-MR^®, and other systems.
• Includes Imricor’s single-use catheters and interventional tools for cardiac procedures.
• Available immediately in CE-marked markets; select configurations in the US now and more pending regulatory approval.
• Scalable platform for potential expansion into new procedures and clinical areas.

What else do investors need to know?

The launch builds on Imricor’s longstanding partnership with Philips, which began in 2012 with joint technology development. The iMR lab solution is designed specifically for cardiac electrophysiology and other interventional cardiac procedures, using MR-guided imaging for improved care.

This innovative, purpose-built approach aims to move MR imaging technology directly into the procedure room, making advanced interventions safer and more effective. The collaboration positions Imricor alongside a major industry player, broadening its reach and potential customer base.

What’s next for Imricor Medical Systems?

Imricor plans to showcase the new iMR lab solution at the ESC Congress 2026 in Munich. The company expects further configurations to be launched in the United States and other geographies as regulatory clearances are achieved.

Management sees this launch as a foundation for future growth, with ambitions to expand the platform into new clinical areas beyond cardiac electrophysiology. The partnership with Philips could pave the way for increased adoption of MR-guided interventions globally.

Imricor Medical Systems share price snapshot

Over the past 12 months, Imricor shares have risen 39%, outperforming the All Ordinaries Index (ASX: XAO).

View Original Announcement

The post Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab appeared first on The Motley Fool Australia.

More reading

• 2 ASX healthcare stocks tipped to return 34% to 63%
• Imricor Medical Systems shares: Philips declares compatibility for iMR products

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.